Highest-materiality recent filing
Sera Prognostics Q1 revenue minimal at $14K; PRIME trial shows 56% reduction in early preterm births
Q1 2026 revenue $14,000 vs $38,000 YoY; net loss $8.4M vs $8.2M; operating expenses $9.4M.
Sera Prognostics Q4 net loss $7.9M; PRIME study shows 56% reduction in preterm births <32 wks
Q4 2025 net loss $7.9M vs $8.6M Q4 2024; full-year net loss $31.9M vs $32.9M.
PRIME study: PreTRM blood test cuts preterm births <32 wks by 56%, NICU admissions by 20%
Randomized trial of 5,018 women: 56% fewer births <32 wks, 32% fewer <35 wks.
Sera Prognostics Q4 revenue $24k; PRIME study meets primary endpoints; raised $57.5M
Q4 2024 revenue $24,000; net loss $8.6M vs $7.9M prior year.
Sera Prognostics prices $50M public offering of 1.25M shares and 11.25M pre-funded warrants
Offering priced at $4.00 per share of Class A common stock and $3.9999 per pre-funded warrant.
Sera Prognostics PRIME study meets both co-primary endpoints; cash $68.2M
Cash, cash equivalents, and marketable securities were approximately $68.2 million as of December 31, 2024 (preliminary).
Sera Prognostics PRIME study topline results published by SMFM
SMFM published an abstract of topline results for the PRIME study on preterm birth risk assessment.
Sera Prognostics Q1 net loss narrows to $8.1M; net revenue nil after adjustments
Net revenue nil after periodic review of accounting estimates for older tests; gross revenue $39K vs $100K YoY.
Sera Prognostics reports Q4/FY2023 results; DSMB stops PRIME study early for efficacy
DSMB recommended stopping PRIME enrollment after co-primary endpoints met significance at interim analysis; preparing manuscript.
Sera Prognostics PRIME study meets efficacy endpoint at interim; enrollment stopped
DSMB recommended stopping PRIME study enrollment after one co-primary endpoint met efficacy stopping criteria at interim.
Sera Prognostics Q3 net loss narrows to $7.2M; appoints permanent CEO and CFO
Revenue of $42k vs $87k YoY; net loss $7.2M vs $10.7M in Q3 2022.
Sera Q2 revenue $123K, net loss $10.5M; appoints interim CEO and CFO
Revenue $123,000 (Q2 2023) vs $78,000 (Q2 2022), up 58% YoY but still minimal.
Sera Prognostics CFO and CCO depart; interim leadership appointed; commercial restructuring
CFO Jay Moyes resigns effective June 7, 2023; Austin Aerts appointed interim CFO.
CEO Gregory Critchfield to retire June 8; Transition Agreement provides $584K severance plus bonus
Retirement as President, CEO and Chairman effective June 8, 2023.
Sera Prognostics CEO Greg Critchfield to retire June 8; Zhenya Lindgardt named interim CEO
CEO Gregory Critchfield retires after 12 years, effective June 8, 2023; remains on board.
Sera Prognostics Q1 revenue $100K, net loss $10.6M; AVERT trial positive
Revenue $100K, up 163% from $38K in Q1 2022.
Sera Prognostics has no exposure to Silicon Valley Bank; no cash or banking relationship
Company does not hold any cash at Silicon Valley Bank (SVB).
Sera Prognostics Q3 2022: Revenue $87k, Net Loss $10.7M; Banner Health contract signed
Q3 revenue $87,000, up from $23,000 YoY; net loss $10.7M vs $9.9M.
Sera Prognostics Q3 net loss widens to $9.9M; cash $82.5M; salesforce scaling to 26 reps
Revenue $23K vs $5K YoY; net loss $9.9M vs $5.1M YoY.
Jeffrey T. Elliott, a member of the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”), notified the Company of his decision to resign from the Board effective as of June 4, 2026
On June 13, 2023, Michael R. Foley, M.D., notified Sera Prognostics, Inc. (the “ Company ”) of his intention to resign from the position of Chief Medical Officer of the Company, effective as of June 30, 2023, and has moved to a consulting role.
Concurrently with Mr. Moyes’s resignation, Austin Aerts, the Company’s current Vice President of Finance and Corporate Controller, was appointed as the interim Chief Financial Officer of the Company, effective June 7, 2023.
On May 22, 2023, Jay Moyes notified Sera Prognostics, Inc. (the “ Company ”) of his intention to resign from the position of Treasurer and Chief Financial Officer of the Company, effective as of June 7, 2023.
On May 24, 2023, Nadia Altomare notified the Company of her intention to resign from the position of Chief Commercial Officer of the Company, effective as of June 9, 2023, and is expected to move to a consulting role to effect a smooth commercial transition.
Gregory C. Critchfield, M.D., M.S. notified the Company of his intention to retire from the position of President and Chief Executive Officer of the Company and Chairman of the Board of Directors, effective as of June 8, 2023
On May 14, 2023, Gregory C. Critchfield, M.D., M. S. notified Sera Prognostics, Inc. (the “ Company ”) of his intention to retire from the position of President and Chief Executive Officer of the Company and Chairman of the Board of Directors (the “ Board ”), effective as of June 8, 2023.
Kim Kamdar, Ph.D., a member of the Board, has been appointed as Chairperson of the Board, effective as of the Retirement Date.
Concurrently with Dr. Critchfield’s retirement, Zhenya Lindgardt, a member of the Board, was appointed as the Interim Chief Executive Officer of the Company, effective June 8, 2023.
On April 11, 2022, the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”) appointed Jane F. Barlow, M.D., MPH, MBA, effective April 11, 2022 (the “Effective Date”), as a director to the Board to serve as a Class I Director with a term expiring at the Company’s 2022 annual meeting of stockholders.
On November 29, 2021, the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”) appointed Sandra A.J. Lawrence, effective November 29, 2021 (the “Effective Date”), as a director to the Board to serve as a Class II Director with a term expiring at the Company’s 2023 annual meeting of stockholders.
On November 8, 2021, the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”) appointed Evguenia (Zhenya) Lindgardt, effective November 8, 2021 (the “Effective Date”), as a director to the Board to serve as a Class III Director with a term expiring at the Company’s 2024 annual meeting of stockholders.
Max materiality 0.85 · Median 0.55 · Most common event earnings